Active, not recruitingPHASE1, PHASE2NCT03155191
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takara Bio Inc.
- Intervention
- TBI-1501(biological)
- Enrollment
- 21 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2017 – 2035
Study locations (11)
- Akita University Hospital, Akita, Akita, Japan
- University Of Fukui Hospital, Yoshida, Fukui, Japan
- Kyushu University Hospital, Higashiku, Fukuoka, Japan
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan
- Kobe City Medical Center General Hospital, Kobe, Hyōgo, Japan
- Mie University Hospital, Tsu, Mie-ken, Japan
- Tohoku University Hospital, Sendai, Miyagi, Japan
- Okayama University Hospital, Okayama, Okayama-ken, Japan
- Jichi Medical University hospital, Shimotsuke-shi, Tochigi, Japan
- Cancer Institute Hospital Of JFCR, Kōto, Tokyo, Japan
- The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03155191 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University